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1.1 Gaucher disease 
Gaucher disease (GD) is a lysosomal disorder which is inherited as an autosomal 
recessive condition with an estimated birth frequency of 1 in 57,000. [1] 
It is caused by mutations in the GBA1 gene which encodes acid glucocerebrosidase; 
reduced activity of this enzyme leads to a build-up of glucosylceramide – mainly in 
the lysosomal compartment of macrophages (giving rise to the so-called ‘Gaucher 
cells’).[2] 
Accumulation of glucosylceramide and related sphingolipids is associated with 
multi-system disease and diverse clinical manifestations. GD has been classically 
divided into three principal types. Type 1 GD (GD1) is mainly characterized by 
visceral manifestations. Signs and symptoms include splenomegaly, hepatomegaly, 
thrombocytopenia, anaemia, bone disease and fatigue. In type 2 (GD2) and type 3 
(GD3) disease there are neurological manifestations ranging from rapidly progressive 
neurological deterioration in GD2 leading to death in the first years of life, to a 
milder neurological phenotype in GD3.[2] 
GD1 is the most common type in populations of European ancestry and Ashkenazi 
Jews in whom it accounts for up to 95% of patients with GD.[2] 
The diagnosis of GD can be a challenge not only due to its rare incidence but also 
due to incomplete penetrance of clinical phenotype, variable onset of the disease 
(both in childhood and in adulthood), and heterogeneity of clinical symptoms (which 
can often involve extra-hematologic organs such as bone compartment). Patients are 
usually referred to hematologists for the presence of cytopenias and/or splenomegaly, 
and differential diagnosis usually takes into consideration other common 
hematological disorders. Anemia and/or thrombocytopenia, and rarely also 
leukopenia, are nearly universal findings among symptomatic patients with GD. 
Cytopenia may occur at any age, and  it usually precedes the appearance of skeletal 
manifestations.[3]  
Disease in different organs may progress at different rates; for example, bone disease 
may occur without significant hematologic/visceral disease and vice versa, and 
severity of disease in one organ does not reliably predict disease in other organs or 
overall disease severity. While some complications of Gaucher disease, such as 
advanced liver disease and portal hypertension and hepatopulmonary syndrome, 
always seem to be associated with a high disease severity score index (SSI), there are 
Università degli Studi di Genova  Dottorato di Ricerca in Scienze Pediatriche 
 5 
other serious Gaucher disease complications, such as pulmonary hypertension, 
osteonecrosis and fragility fractures that can occur in patients with a relatively low 
SSI. Similarly, a number of comorbidities are associated with Gaucher disease, such 
as multiple myeloma and other cancers, Parkinson’s disease, peripheral neuropathy, 
and gallstones, that do not seem to relate to overall disease severity as conventionally 
defined. Many aspects of Gaucher disease are not fully understood, including an 
understanding of the pathogenesis and management of neuronopathic disease, the 
pathogenesis of bone disease, and factors that underlie the variability of Gaucher 
disease manifestations between patients, even of the same genotype.[4] 
Currently, two different therapeutic approaches for the treatment of GD1 are used: 
enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). 
Intravenously administered ERT is targeted to macrophages and increases the 
breakdown of the accumulated glycolipids, while SRT reduces the amount of 
glucosylceramide by inhibiting its synthesis, representing an oral alternative to ERT. 
Both treatments have proven to be very effective in the treatment of the visceral and 
haematological complications of the disease,[5][6][7][8] since decrease in splenic 
and hepatic size and improvement in cytopenias are usually apparent after 6 months 
of treatment.[9] Nonetheless, in some patients thrombocytopenia may persist despite 
treatment and a possible immunological mechanism has been hypothesized. In the 
last years, a growing interest in immune system involvement in Gaucher disease is 
developing.   
 
1.2 Autoimmune Lymphoproliferative Syndrome (ALPS) 
Autoimmune lymphoproliferative syndrome (ALPS) is a rare congenital disease 
secondary to a defect of FAS-mediated apoptosis. 
ALPS has very low incidence, even if its exact prevalence is still unknown. 
According to the revised criteria for the diagnosis and classification of ALPS from 
2009 International Workshop at the National Institutes of Health (NIH), only 
approximately 500 patients with ALPS originating from more than 300 families have 
been investigated all over the world.[10]  
It is a genetic disorder caused by germline (62%) or somatic FAS mutations and by 
mutations in CASP10 and FASLG. The median age at first disease onset is 24 
months; however, with increasing awareness of this disease, adult ALPS patients are 
also now being diagnosed more frequently.[11]  
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ALPS is often misdiagnosed due to variable phenotypic expressions and the overlap 
of symptoms with many other haematological disorders.[12] 
Lymphoproliferation is the most common clinical manifestation in ALPS, presenting 
with lymphadenopathy, hepatomegaly or splenomegaly.[13] Lymphoproliferation in 
ALPS must be chronic (>6 months) and neoplastic and infectious etiology should be 
ruled out. If an isolated lymphadenopathy is present, it can affect at least two distinct 
nodal regions. A moderate to massive splenomegaly is detected in more than 85% of 
patients, and mild to moderate hepatomegaly is also common in ALPS patients.  
Autoimmunity is the second most common clinical manifestation in ALPS patients 
and it frequently requires medical intervention. Autoimmunity usually affects over 
70% of patients. Many patients have multiple cytopenias such as Coombs positive 
autoimmune hemolytic anemia (AIHA) and immune mediated thrombocytopenia. In 
addition, rashes especially urticarial, immune-mediated pulmonary fibrosis, and SLE 
are also reported in ALPS. Other autoimmune manifestations including autoimmune 
nephritis, hepatitis, gastritis, arthritis, and uveitis are infrequently observed.[14] 
The elevation of T cell receptor (TCR) αβ+/CD4-/CD8- T cells in peripheral blood 
and lymphoid tissues is the most significant laboratory characteristic of ALPS 
patients, but some patients may have normal numbers. The population of TCR αβ+ 
DNT cells required for the diagnosis is higher than or equal to 1.5 % of total 
lymphocytes or 2.5%of CD3+ T lymphocytes.[15]  
The apoptotic assay of abnormal lymphocytes is previously thought to be the gold 
standard for the diagnosis of ALPS and documented in the required diagnostic 
criteria. Apoptotic assay measures the percentage of activated primary lymphocytes 
undergoing apoptosis after FAS activation (using recombinant Fas ligand/TCR re-
stimulation/cytokine starvation).[16]. Approximately 50% or less cell death than the 
control is considered as abnormal.[15] However, this test is expensive and is 
available in only few laboratories. Moreover, patients with somatic mutation in FAS 
and germline FASLG mutations have normal Fas-induced apoptosis assay, so this 
test is no longer considered as mandatory in the diagnosis of ALPS.[17] 
Serum IL-10, IL-18, soluble FAS ligand (FasL), and vitamin B12 are commonly 
elevated in ALPS patients with FAS mutation and can be useful diagnostic 
biomarkers.[18] [19] 
Recent studies have demonstrated that the presence of elevated TCR αβ+-DNT cells 
combined with high serum or plasma levels of either IL-10, IL-18, soluble FAS 
ligand (sFASL), or vitamin B12 can predict the mutation of germline or somatic FAS 
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gene with an accuracy rate of 85–97%. Due to their high specificity, these 
biomarkers have been included in the diagnostic criteria.[15] 
Since the investigators from NIH have established a triad of criteria for the diagnosis 
of ALPS in 1999, important research advances have been achieved. In 2009, an 
international workshop from NIH has revised the criteria for the diagnosis and 
classification of ALPS and published the revised criteria in 2010.[15]  
The presence of both required criteria plus one primary accessory criterion allows a 
definitive diagnosis of ALPS, while both required criteria plus one secondary 
accessory criterion suggest a probable diagnosis of ALPS. 
Required criteria: 
1. Chronic (> 6 months), nonmalignant, noninfectious lymphadenopathy or 
splenomegaly or both 
2. Elevated CD3+TCR+CD4-CD8- DNT cells (≥1.5% of total lymphocytes or 2.5% 
of CD3+  lymphocytes) in the setting of normal or elevated lymphocyte counts 
Accessory criteria: 
Primary: 
1. Defective lymphocyte apoptosis (in 2 separate assays) 
2. Somatic or germline pathogenic mutation in FAS, FASLG, or CASP-10 
Secondary: 
1. Elevated plasma sFASL levels (>200 pg/mL) OR elevated plasma interleukin-10 
levels (>20 pg/mL) OR elevated serum or plasma vitamin B12 levels (>1500 ng/L) 
OR elevated plasma interleukin-18 levels >500 pg/mL 
2. Typical immunohistological findings as reviewed by an experienced 
hematopathologist 
3. Autoimmune cytopenias (hemolytic anemia, thrombocytopenia, or neutropenia) 
AND elevated immunoglobulin G levels (polyclonal hypergammaglobulinemia) 
4. Family history of a nonmalignant/noninfectious lymphoproliferation with or 
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1.3 Study reasons and Objectives 
As clinical manifestation of GD can be underhand, in some cases, phenotype can 
mimic benign lymphoproliferative disorders such as ALPS or other similar disorders 
whose phenotype does not completely fulfill the ALPS diagnostic criteria that are 
usually reported as ALPS-like syndromes. The knowledge of these groups of 
diseases and other primary immune dysregulation disorders (PIRDs) has greatly 
increased in the last few years, but no patients with such phenotype leading to a 
diagnosis of GD have been reported so far. 
For many years the impairment of monocytes and their transformation to 
inflammatory subsets of macrophages and dendritic cells has been considered the 
main pathogenic mechanism of GD; however, in the last few years, the involvement 
of other players of immune response, such as lymphocytes, including T, B, and 
natural killer (NK) cells, has been demonstrated, suggesting a more complex 
scenario.[20][21][22] Nair demonstrated that type II NKT cells with a T follicular 
helper cell phenotype are increased in an animal model of GD and in GD 
patients.[22] It is postulated that dendritic cells take up glucosylceramide and 
glucosylsphingosine release from Gaucher cells, migrate to lymph nodes and present 
their cargo via CD1d to type II NKT cells. This initial trigger, together with signals 
from B lymphocytes, drive the activation and differentiation of type II NKT cells, 
that promote differentiation of B lymphocytes into plasma cells, with associated 
gammopathy and production of glucosylceramide and glucosylsphingosine specific 
IgG auto-antibodies.[20] Recently, Pandey has pointed to an unexpected player in 
GD: the complement system.[23] He showed that glucosylceramide-immunocomplex 
leads to classical pathway activation, eventually leading to systemic C5 cleavage and 
C5a generation. In addition, immunocomplexes also bind to activating FcγRs 
expressed on phagocytes. FcγR aggregation induces local C5 production and non-
canonical C5 proteolysis by a cell-specific protease leading to C5a formation. The 
binding of systemically or locally-generated C5a to C5aR1 enhances the 
accumulation of glucosylceramide and glucosylsphingosine within phagocytes 
through increased expression of glucosylceramide synthase, driving a vicious cycle 
that fuels the autoimmune response directed against these sphingolipids. Furthermore 
the activation of the C5a/C5aR1 axis in dendritic cells upregulates costimulatory 
molecules (CD80/CD86/CD40) and drives the activation of NKT effector cells (NKT 
Università degli Studi di Genova  Dottorato di Ricerca in Scienze Pediatriche 
 9 
Eff) with Th1 (IFN-γ) and Th17 (IL-17A/F) signatures, eventually sparking chronic 
inflammation and tissue involvement in GD.[23] Pandey also demonstrated that the 
interruption of this vicious cycle at the level of C5a/C5aR1 interaction is sufficient to 
massively reduce cellular glucosylceramide accumulation and protect from death in 
genetic and pharmacologically induced GD models.[23]   
 
In summary, these laboratory results suggest a fundamental role of immunological 
abnormalities in the pathogenesis of GD.  
On the basis of a fortuitous diagnosis of GD in a child previously diagnosed with 
ALPS and of the frequent phenotypic overlap between these conditions, we decided 
to investigate the possible presence of an apoptosis defect in GD patients. 
The primary objective of the present study was the identification of an ALPS-like 
immunophenotypic pattern in a wide cohort of GD patients followed in Giannina 
Gaslini Institute in Genoa. 
Secondary objectives were: 
- the comparison of immunological alterations between naïve and treated patients 
- the correlation of immunological alterations with Gaucher disease activity 
parameters  
- the study of FAS-mediated apoptosis function and caspase activation in a subgroup 
of patients with indirect signs of apoptosis impairement. 
 
  




























All the patients affected by GD evaluated in Rare Diseases Unit of Giannina Gaslini 
Institute in a period of 18 months were included in the study. 
The inclusion criteria were a certain diagnosis of GD (by enzyme assay on 
leukocytes or lymphocytes or fibroblasts culture and characterization of GBA1 
pathogenic variants) and the informed consent to the participation to the study. 
No exclusion criterion was established.  
For each patient, the main GD parameters collected at last visit in Gaslini Institute 
were available: haemoglobin concentration, white blood cell count, platelet count, 
serum chitotriosidase, spleen and liver volume meausered by MRI, history of 
splenectomy, bone marrow infiltration and osteonecrosis evaluated through MRI, 
history of pathological fractures, bone mineralization based on DEXA, diagnosis of 
respiratory failure, pulmonary hypertension, peripheral neuropathy, Parkinson’s 
disease or parkinsonism. On the basis of these parameters, the Gaucher Disease 
Severity Score Index - Type I (GauSSI-I) score was calculated for each patient 
(Table 1).[24]   
A flow panel including 4 specific parameters suggestive of ALPS (CD3+CD4-CD8-
TCRαβ+, known as “double negative T cells” [DNTs], >1.5%; CD19+CD27+ <10%; 
B220+DNTs >60%; CD3+CD25+/CD3+HLA-DR+ ratio <1) and serum biomarkers 
(FAS ligand, IL-18, IL-10, and vitamin B12) evaluation were used as a screening to 
identify immunological features of ALPS in patients with GD. [25][26][27][28][29] 
In those who showed at least 3 ALPS-like immunophenotypic parameters, both FAS-
induced apoptosis and caspase activation were assayed in Epstein-Barr virus (EBV)-
immortalized B-cell lines. 
Furthermore, NK cells, NKT-like cells (CD3+ CD16+CD56+), CD19+ B cells, 
TCRγδ+, Treg, T naive and T memory cells were studied. 
Autoimmune screening included antinuclear, antiextractable nuclear antigen, 
antithyroid peroxidase, antithyroglobulin, and antitissue transglutaminase 
immunoglobulin antibodies testing, along with direct and indirect Coombs tests. In 
the case of thrombocytopenia or neutropenia, antiplatelet or antineutrophil 
antibodies, respectively, were also tested. 
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Biological samples were provided by Gaslini Biobank (Target Biobank P00-IGG-
GB, request ID 509 and 620, Genoa, Italy); for tests requiring biological material that 
was not frozen, supplemental blood samples were donated during routine monitoring 
of the disease. All samples were donated with the patient’s or parent/tutor’s written 
informed consent. 
 
2.2 Laboratory methods 
2.2.1 Lymphocyte immunophenotype 
Peripheral lymphocyte subsets were evaluated from whole blood using an 8-colour 
immunostaining panel and by lyse and wash procedure.  Briefly, 50 µl of EDTA 
anticoagulated whole blood has been incubated with surface fluorochrome-labelled 
monoclonal antibodies (mAbs) for 20 min at 4°C and lysed with FACS Lysing 
solution (Becton Dickinson, BD) for10 min at room temperature (RT). Data 
acquisition and analysis have been performed on a FACS Canto II flow cytometer 
(BD) equipped with three lasers a Blue (488-nm, air-cooled, 20-mW solid state), a 
Red (633-nm, 17-mW HeNe), a Violet (405-nm, 30-mW solid state) and FACS 
Diva™ software (BD). Peripheral lymphocyte subsets were evaluated using the 
following RUO mAbs: CD3, CD4, CD8, CD16-56, CD19, CD20, CD27, TCRαβ, 
TCRγδ, HLA-DR, CD25, CD45, CD45RO, CD45RA (all BD). 
Fluorochromes differently combined for eight colours antibody panels were: APC, 
APC-H7, FITC, PE, PE-Cy7, PerCP-Cy5.5, V450, V500. 
2.2.2 Interleukin-18, interleukin-10, and FAS ligand 
IL-18, IL-10, and FAS ligand were tested using commercially available enzyme-
linked immunosorbent assay kits (MBL, Woburn, Mass; Invitrogen, Waltham, Mass; 
Abnova, Taipei, Taiwan, respectively). 
 
2.2.3 FAS-induced apoptosis and caspase activation 
The patients’ EBV-immortalized B cells were treated with FAS ligand (10 ng/mL; 
Enzo Life Science) for 24 hours to induce apoptosis, and cell death was measured by 
a cytofluorimeter. Apoptosis pathway function was evaluated by the Western-blot 
analysis of CASP10, CASP8, and PARP proteins using rabbit monoclonal anti-
CASP10 antibodies (Abcam), mouse monoclonal anti-CASP8 (1C12), and rabbit 
polyclonal anti- PARP (Cell Signaling Technology). 




2.3 Statistical analysis 
Comparison of qualitative variables was performed by applying the Chi-square test 
or the Fisher exact test. Comparison of quantitative variables between two groups 
was made by the Mann–Whitney U test. 
All correlations were assessed using Spearman’s rank order correlation coefficient 
(rs). For the purpose of this analysis, correlations >0.8 were considered very high, 
correlations ranging from 0.6 to 0.79 were considered high, correlations ranging 
from 0.4 to 0.59 were considered moderate and correlations <0.4 were considered 
weak.  
All statistical tests were two-sided and p<0.05 was considered statistically 
significant.  
The statistical package used was Statistica (StatSoft, Tulsa, Oklahoma, USA).  
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3.1 Index case 
A 12-year-old child with a history of ALPS diagnosed in another center was referred 
to our Institution for a second evaluation. 
The patient phenotype completely fulfilled the diagnostic criteria of ALPS reported 
by Oliveira, [15] since he presented with chronic splenomegaly since the age of 22 
months, severe persistent thrombocytopenia, increased count of DNTs (2.8%) and 
defective lymphocyte apoptosis in two different samples (FAS-induced cell death 0% 
and 13%). No pathogenic mutation was found in FAS, CASP-10 and FASLG genes. 
Surprisingly, bone marrow biopsy showed the presence of a huge amount of 
engorged histiocytes PAS+ and CD68+, identified as “Gaucher cells”. 
Chitotriosidase was significantly increased (14760 nmol/ml/h), βglucocerebrosidase 
activity was markedly reduced (0.9 nmol/mg/h) and GBA1 gene analysis showed a 
compound  heterozigosity (N370S/G202R), leading to a diagnosis of GD associated 
to ALPS. MRI showed femoral bone marrow infiltration bilaterally. ERT was started 
(50 UI/Kg i.v. every other week) and it was able to reverse the clinical signs and 
symptoms and even the main immunological abnormalities previously noticed 
(Figure 1).  
 
Figure 1. Changes in platelet count, chitotriosidase, spleen volume and immunological 
parameters during the 2.5 years following the start of ERT in the first patient diagnosed with 
ALPS affected by Gaucher disease. 
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On the basis of this unusual phenotypic overlap, we decided to investigate the ALPS-
like immunophenotypic pattern, FAS-mediated apoptosis function, and caspase 
activation in a wider cohort of patients with GD, with the aim of identifying the 
presence of apoptosis impairment. 
 
3.2 GD population 
In total, 41 patients aged 1.6 to 71.5 years were enrolled. Eight patients were 
treatment-naïve and 33 were treated with ERT o SRT. 
Demographic characteristics and a summary of GD-related parameters (GBA1 
analysis result, age at disease onset, treatment duration, and GauSSI-I score) for each 
patient are reported in Table 1. 
 
Table 1. Detailed demographic features and Gaucher disease related parameters, including 
results of molecular analysis of GBA1 gene and GauSSI-I score (Gaucher Disease Severity 
Score Index – Type 1), for each patient included in the study. GauSSI-I score is not validated 
for children (not applicable, NA). Age at onset of the disease is NA in asymptomatic patients 

















1 m 1.6 L444P N370S 0.5 NO NA NA 
2 f 6.6 N370S E388K NA NO NA NA 
3 f 10.5 N370S E388K NA NO NA NA 
4 f 13.5 N370S N370S NA NO NA NA 
5 m 12.6 N370S G202R 1.9 NO NA NA 
6† f 14.7 S271G ? 10.0 NO NA NA 
7 f 37.0 N370S F213I 23 NO NA 9 
8 m 52.4 L444P G46E 5.0 NO NA 8 
9 f 65.4 N370S 
D409H+H
255Q 
57.0 NO NA 4 
10 f 65.8 N370S R120W 49.0 NO NA 6 
11† f 2.3 E388* D409H 0.3 YES 1.3 NA 
12† f 5.7 L444P L444P 4.0 YES 5.0 NA 
13 f 5.8 L444P N370S 3.0 YES 2.5 NA 
14 m 7.2 L444P I402T 4.4 YES 2.4 NA 
15† f 11.2 L444P L444P 1.0 YES 8.1 NA 
16 f 13.1 N370S 
IVS2+1G
>A 
8.0 YES 0.8 NA 
17 f 13.9 L444P W312S 6.0 YES 6.4 NA 
18 m 16.0 N370S N370S 2.6 YES 13.3 NA 
19 f 16.5 L444P W312S 9.0 YES 6.4 NA 
20 f 17.2 N370S RecNciI 9.0 YES 6.8 NA 
21 f 19.1 G46E G202R 5.0 YES 12.7 3 
22 m 20.8 N370S IVS2G>A 5.0 YES 15.4 0 
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23 m 21.8 N370S L444P 10.0 YES 11.9 0 
24 m 25.3 N370S IVS2G>A 5.0 YES 18.2 0 
25 f 28.7 L444P W312S 8.0 YES 16.4 1 
26† m 31.5 L444P F213I 3.0 YES 25.8 0 
27 f 32.9 N370S R131C 11.0 YES 18.7 3 
28 m 35.7 N370S RecNciI 3.0 YES 24.6 0 
29 m 36.7 N370S R131C 2.5 YES 12.3 3 
30 f 38.3 N370S G195R 35.0 YES 2.7 0 
31 m 41.6 N370S R131C 6.0 YES 13.3 3 
32 m 49.6 N370S L444P 15.0 YES ND 0 
33 m 50.0 N370S L444P 32.0 YES 12.4 2 
34 f 52.6 N370S rec NciI 35.0 YES 12.8 1 
35 f 59.0 N370S L444P 41.0 YES 15.3 1 
36 m 59.0 N370S 
D409H+H
255Q 
40.0 YES 17.5 1 
37 f 67.1 N370S L444P 40.0 YES 21.3 4 
38 f 67.2 N370S N370S 56.0 YES 7.2 0 
39 f 69.4 N370S N370S 50.0 YES 12.8 1 
40 f 69.8 N370S ? 54.0 YES ND 3 
41 m 71.5 N370S S366R 60.0 YES 9.2 3 
†GD3 patients. m: male. f: female. NA: not applicable. TRT: treatment. GauSSI-I score: 
Gaucher Disease Severity Score Index- Type I.[24] 
 
Nine (21%) and 7 (17%) of the patients had high levels of DNTs and B220+DNTs, 
respectively. Levels of DNTs and B220+DNTs were more frequently raised in naïve 
subjects (p=0.040 and p=0.031, respectively; Figure 2) and in patients with early 
onset of the disease (p=0.046 and p=0.011, respectively) compared with treated 
patients and patients with a late onset phenotype.  
 
Figure 2. Comparison of DNTs and B220+DNTs in treated and untreated GD patients. 
 
 
No significant correlation was found between DNTs and B220+DNTs and GauSSI-I 
score or other Gaucher disease severity parameters. 
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All patients showed normal levels of IL-10 and serum FAS-L, but 14 of 41 patients 
(34%) had IL-18 levels of >500 pg/mL, with a trend for higher levels in untreated 
versus treated patients, although this was not statistically significant (p=0.06). 
Overall, 10 of 41 (24%) patients showed an ALPS-like immunological pattern (at 
least 3 of 4 features of the ALPS panel), that was more frequent in untreated patients 
(p=0.003) and in patients with an earlier onset of disease (p=0.01).  
FAS-induced apoptosis and caspase activation were further evaluated in these 
patients, with 7 out of 10 (70%) shown to be defective (Figure 3).  
 
Figure 3. (A) Cell death and (B) apoptosis pathway impairment after FAS ligand-induced 




Surprisingly, 37 of 41 patients (90%) had CD8+NKT-like cells that were absent or 
lower than normal values for age (Figure 4).  
 
Figure 4. Reduction of NKT-like cells below the normal values for age in the majority of 
patients with Gaucher disease, irrespective of treatment. 
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The only patient evaluated before and after treatment showed complete 
normalization of lymphocyte subsets after ERT. A comparison of the main clinical 
and laboratory parameters between treated and untreated patients is shown in Table 
2. Lymphocvtes subsets and ALPS immunophenotipic features and biomarkers for 
each patient included in the study are reported in Table 3 and Table 4, respectively. 
 







Age (years) 14.1 (11.0 - 48.6) 30.1 (16.3 - 51.3) 0.286 
Age at onset (years) 10.0 (3.5 - 36.0) 8.0 (4.2 - 35.0) 0.971 
Age at start of treatment (years) NA 11.1 (5.7 - 37.6) NA 
Treatment duration (years) NA 12.7 (6.6 - 17.0) NA 
ERT dosage (U/Kg/2 weeks) NA 31.0 (29.0 - 38.5) NA 
Chitotriosidase (nmol/ml/h)  
[n.v. 43.5±23.2] 
5120 (1242 - 
10660) 
480 (320 - 930) 0.223 
Platelets (el. x103/mm3) [n.v. 150-400] 188 (93 - 265) 210 (162 - 241) 0.354 
Hemoglobin (g/dL)  
[n.v.:m 13.5-17-5; f 12.0-15.5] 
12.8 (11.3 - 13.5) 14.2 (13.5 - 15.2) 0.002* 
Ferritin (ng/mL) [n.v. 15-50] 180 (103 - 780) 98 (37 - 170) 0.119 
Spleen volume (cc)  
[n.v.=0.2% of total body weight] 1 
973 (694 - 1124) 247 (216 - 270) 0.009* 
Spleen volume (multiples of normal) 1.3 (1.0 - 4.9) 1.5 (1.0 - 2.0) 0.829 
GauSSI-I score [n.v. 0] 2 7.0 (5.5 - 8.3) 1.0 (0.0 - 3.0) 0.002* 
NK-T like cells (% total lymphocytes) 3 0.8 (0.5 - 1.9) 0.9 (0.3 - 1.4) 0.988 
Double negative T-cells (% total 
lymphocytes) [n.v.<1.8] 
1.5 (1.2 - 2.0) 1.0 (0.8 - 1.4) 0.040* 
B220+ cells (%  TCRαβ+ lymphocytes) 
[n.v.<60] 
55.7 (54.5 - 70.0) 44.7 (40.8 - 55.1) 0.031* 
B-memory cells (% total B lymphocytes) 
[n.v.>15] 
13.3 (10.0 - 21.4) 24.1 (15.8 - 32.4) 0.063 
CD3CD25+/CD3HLA-DR+ lymphocytes 
ratio [n.v.>1] 
1.0 (0.5 - 1.3) 1.2 (0.7 - 1.7) 0.472 
IL-18 (pg/mL) [n.v. 36-258] 1350 (1000 -; 
1350) 
350 (139 -; 469) 0.618 
IL-10 (pg/mL) [n.v. <1] <1 (<1 - <1) <1 (<1 - 1.5) 0.731 
sFASL (pg/mL) [n.v. 0] 0 (0 - 0) 0 (0 - 0) 0.480 
Vitamin B12 (pg/mL) [n.v. <663] 429 (322 - 578) 438 (315 - 558) 0.815 
Apoptosis defect parameters (n.) 4 3 (2 - 3) 1 (0 - 2) 0.003* 
NA: not applicable. n.v.: normal values. ERT: enzyme replacement therapy.  
GauSSI-I score: Gaucher Disease Severity Score Index – Type I. *p<0.05 
1Spleen volume has been measured by MRI only in adults. 
 2GauSSI-I score is not applicable in children and has been calculated only for adults.  
3Normal values for NK-T like cells vary deèending on age. 
 4Apoptosis defect parameters include: double negative T-cells ≥1.8%, TCRαβ+B220+ cells 
≥60%, B-memory cells <15%, CD3CD25+/CD3HLA-DR+ lymphocytes ratio <1, IL-18 >500 
pg/mL, IL-10 >20 pg/mL, sFASL > 200 pg/mL, vitamin B12 > 663 pg/mL, abnormal FAS-
apoptosis. 
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Table 3.  Lymphocvtes subsets for each study patient, expressed as percentage of total 











B cells  
(%) 
[n.v.10-22] 






1 55.8 (L) 32.0 (L) 17.6 (L) 26.3 (H) 15.8 0.1 (L) 
2 73.1 35.2 27.3 16.9 10.5 0.4 (L) 
3 73.9 34.5 31.0 (H) 17.1 8.8 (L) 0.8 (L) 
4 77.8 50.3 (H) 18.3 (L) 14.0 7.9 (L) 0.6 (L) 
5 80.1 (H) 34.4 35.4 (H) 15.0 6.4 (L) 2.6 (L) 
6† 70.0 30.0 (L) 27.9 13.0 15.4 3.1 
7 85.9 (H) 52.2 28.5 (H) 10.5 3.3 (L) 1.2 (L) 
8 66.0 33.0 31.0 (H) 21.0 12.6 2.1 (L) 
9 71.5 55.0 (H) 12.7 (L) 9.0 (L) 6.0 (L) 0.0 (L) 
10 70.6 36.0 33.0 (H) 14.6 15.0 0.7 (L) 
11† 64.4 45.0 16.0 (L) 25.3 (H) 8.3 (L) 0.1 (L) 
12† 70.4 33.8 23.2 18.9 8.7 (L) 0.0 (L) 
13 69.5 31.0 (L) 28.2 (H) 20.7 8.1 (L) 0.3 (L) 
14 82.5 (H) 37.7 28.4 (H) 11.1 5.4 (L) 0.8 (L) 
15† 63.6 40.2 15.5 (L) 18.7 17.3 (H) 0.3 (L) 
16 76.4  49.7 (H) 16.7 (L) 16.3 7.4 (L) 0.8 (L) 
17 76.3  46.0 24.0 13.8 10.3 0.2 (L) 
18 81.9 (H) 42.5 25.7 11.7 6.0 (L) 0.9 (L) 
19 72.8 43.0 22.0 13.3 13.1 0.0 (L) 
20 71.3 43.0 24.3 10.0 19.0 (H) 1.4 (L) 
21 83.1 (H) 48.6 30.2 (H) 9.8 (L) 6.7 (L) 1.0 (L) 
22 70.6 44.0 21.4  - 17.8 (H) 0.4 (L) 
23 68.8 40.0 24.5 7.9 (L) 22.6 (H) 4.6 
24 80.0 (H) 48.0 23.3  - 10.0 1.5 (L) 
25 85.5 (H) 45.0 33.2 (H)  5.7 (L) 8.5 (L) 0.0 (L) 
26† 73.9 24.5 (L) 43.4 (H) 10.7 14.6 3.4 
27 74.3  45.0 25.0 9.4 (L) 16.2 (H) 1.5 (L) 
28 62.4 20.0 (L) 23.0  0.5 (L) 5.9 (L) 0.5 (L) 
29 66.6 43.0 21.1 13.0 20.5 (H) 1.1 (L) 
30 74.3 48.0 14.5 (L) 7.7 (L) 17.4 (H) 4.0 
31 66.2 34.0 30.2 (H) 7.3 (L) 26.0 (H) 0.7 (L) 
32 75.3 47.0 27.9 19.4  6.1 (L) 0.1 (L) 
33 67.9  30.3 (L) 33.0 (H) 3.3 (L) 5.3 (L) 3.2 
34 73.9 44.2 26.0 14.6 15.2 1.2 (L) 
35 79.0 (H) 61.0 (H) 14.9 (L) 9.5 (L) 11.6 0.5 (L) 
36 63.7 37.7 21.5 15.6 19.9 (H) 2.5 (L) 
37 68.0 39.2 25.0 16.3 13.6 0.2 (L) 
38 73.8 37.5 34.0 (H) 11.5 13.4 1.1 (L) 
39 75.6 48.6 23.5 15.4 9.0 (L) 0.9 (L) 
40 61.5 46.0 13.4 (L) 6.4 (L) 32.2 (H) 0.9 (L) 
41 53.3 (L) 33.0 17.5 (L) 6.1 (L) 41.4 (H) 1.3 (L) 
†GD3 patients. ND: not determined. n.v.: normal values. (H): higher than normal range. (L): 
lower than normal range. 
*NK-T like cells (% of total lymphocytes) n.v. for age: >3.4 (>16 years), >2.6 (5-16 years), 
>1.7 (2-5 years), >0.8 (1-2 years). 
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Table 4. ALPS immunophenotipic features (Table 4A) and biomarkers (Table 4B) 






















1 64% 2.0 (H) 91.3 (H) 10.0 (L) 0.4 (L) 
2 44% 1.9 (H) 56.8 20.6 1.1 
3 39% 2.1 (H) 54.5 14.2 (L) 0.4 (L) 
4 60% 1.2 74.4 (H) 12.4 (L) 0.9 (L) 
5 100% (H) 2.8 (H) 56.0 9.4 (L) 1.5 
6† ND 1.0 52.5 5.6 (L) 0.4 (L) 
7 52% 1.5 94.0 (H) 69.0 1.4 
8 100% (H) 1.4 55.0 10.0 (L) 2.0 
9 ND 1.2 27.0 21.6 1.0 
10 43% 1.0 55.3 29.0 1.1 
11† 74% 1.4 95.0 (H) 16.5 1.2 
12† 52% 2.0 (H) 44.7 11.5 (L) 0.7 (L) 
13 69% 1.1 53.7 11.0 (L) 0.3 (L) 
14 57% ND ND ND ND 
15† 58% 1.2 40.5 21.6 1.4 
16 57% 0.8 41.5 9.7 (L) 2.0 
17 ND 1.4 47.5 18.7 1.3 
18 60% 0.8 44.0 11.8 (L) 0.5 (L) 
19 ND 1.1 42.3 21.6 2.9 
20 ND 1.0 50.6 26.5 1.8 
21 ND 0.9 60.6 (H) 27.6 1.1 
22 61% 1.6 36.3 24.1 2.0 
23 56% 0.7 55.6 13.6 (L) 1.2 
24  ND 2.2 (H) 32.9 24.8 2.7 
25 74% 0.9 58.0 33.0 0.8 (L) 
26† ND 1.6 58.0 42.7 1.0 
27 ND 2.0 (H) 43.0 44.0 1.5 
28 73% 2.9 (H) 60.0 (H) 0.0 (L) 0.7 (L) 
29 28% 0.9 52.5 12.9 (L) 0.7 (L) 
30 88% (H) 0.8 33.6 47.0 2.0 
31 19% 1.4 64.0 (H) 30.0 0.6 (L) 
32 ND 0.3 31.0 63.9 1.4 
33 52% 0.8 59.0 56.0 0.5 (L) 
34 78% 0.8 10.0 41.5 1.2 
35 26% 1.0 30.0 46.5 5.2 
36 34% 2.5 (H) 53.0 15.6 1.3 
37 ND 1.1 41.6 18.5 1.0 
38 43% 1.4 50.0 22.0 0.2 (L) 
39 ND 0.6 43.0 30.6 0.4 (L) 
40 ND 0.7 34.3 30.7 2.1 
41 ND 0.7 46.6 25.0 0.5 (L) 








sFASL  (ng/mL) 
[n.v.<200] 
Vitamin B12 (pg/mL) 
[n.v.<663] 
1  825 (H) <1 ND 623 
2 1000 (H) <1 0 605 
3 275 <1 0 ND 
4  900 (H) <1  ND 498 
5 ND ND ND 359 
6† 2182 (H) <1 0 ND 
7  900 (H)  <1 0 309 
8 1350 (H) <1 0 241 
9  550 (H)  3 0 ND 
10 1350 (H) <1 0 ND 
11†  600 (H)  2 0 883 (H) 
12† 350  3 0 ND 
13  2200 (H) 15   ND 941 (H) 
14 175 <1  0 636 
15† 450  3 0 ND 
16 1000 (H) <1 0 645 
17 525 (H) <1 0 450 
18  1200 (H) <1  ND 508 
19 650 (H) <1 0 379 
20 475 <1 0 301 
21 132 <1 0.6 ND 
22 95 <1 0 ND 
23 ND ND ND 532 
24 100 <1 0 ND 
25 250 <1 0 474 
26† 135 <1 0 490 
27 375 0 ND ND 
28 250 <1 0 446 
29 400 <1 0 251 
30 15 <1  ND 266 
31 400 2 0 212 
32 150 <1 0 266 
33 450 <1 0 327 
34 125 <1 0.2 301 
35 500  2 0 437 
36 130  2 0 416 
37 ND ND ND ND 
38 300 <1 0 706 (H) 
39 500 <1 0 654 
40 500 <1 0 319 
41 350 <1 0 438 
†GD3 patients. ND: not determined. n.v.: normal values. (H): higher than normal range. (L): 
lower than normal range. 
*Performed on fresh activated T-cells stained by direct immunofluorescence with  anti-Fas 
monoclonal antibody and analysed by cytometry . 
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Autoimmunity parameters were negative in most patients, except for 2 cases of 
antinuclear antibody positivity and 3 cases of antithyroid peroxidase and 
antithyroglobulin antibodies; antitissue transglutaminase immunoglobulin A 
antibody and direct and indirect Coombs tests were always negative, as well as 
antiplatelet antibodies. Antineutrophil antibodies were never tested because no case 
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This study shows that untreated patients with GD have an immune-dysregulation 
pattern secondary to an FAS-mediated apoptosis defect, adding novel information to 
the already complex pathogenic scenario of this rare disease. This highlights that 
hematologists and immunologists should be aware of the possibility of GD among 
referrals for ALPS. Some common clinical issues of both disorders, such as 
thrombocytopenia and splenomegaly, should be evaluated not only as an overlapping 
sign of different diseases, but also as the result of a common pathogenic pathway 
impaired by different causes.  
The reasons for a FAS-mediated apoptosis defect in patients with GD are still 
unclear. We can speculate that the well-known alteration of cell-membrane lipid 
homeostasis in GD may play a role in such a phenomenon, as already shown in the 
case of toll-like receptors.[30] Moreover, it is well known that sphingolipids are key 
players in many major cell biological functions and that ceramide, a central molecule 
of sphingolipid metabolism, plays a crucial role in programmed cell death, being a 
mediator of both intrinsic and extrinsic apoptosis pathways.[31] In fact, the increased 
generation of ceramide in response to cellular stress and apoptosis triggers, such as 
tumor necrosis factor or FAS ligand, results in cell death by caspase activation. 
Conversely, glucosylceramide, which is increased in GD because of a GBA defect, is 
an antiapoptotic sphingolipid (Figure 5).[32] There is growing evidence indicating 
that, via glucosylceramide synthase (GCS) overexpression, glucosylceramide 
accumulates in multidrug-resistant tumors and cancer cell line[33][34] and that the 
consequent abnormal ceramide/glucosylceramide ratio is the cause of drug-induced 
apoptosis resistance; indeed, the inhibition of GCS reverses drug resistance in cancer 
cells, thus decreasing the levels of glucosylceramide and enhancing ceramide-
induced apoptosis.[35] Although this has not been proved in our patients and needs 
further study, we may speculate that the abnormal proapoptotic/antiapoptotic lipid 
ratio, due to defective glucosylceramide degradation, may play an important role in 
the observed apoptosis defect because it is also known that ERT or inhibition of GCS 
by eliglustat,[36] leading to restoration of the ceramide/glucosylceramide ratio, 
induces 
apoptosis.  
The presence of an apoptosis defect and immune dysregulation in this rare disease 
may also explain the previously reported cases of patients with GD with immune 
thrombocytopenic purpura,[37][38] which, in addition to splenomegaly, can 
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represent a crucial factor for misdiagnosis versus other immunedysregulation 
syndromes that, in turn, can also be underhand, being secondary to genetic defects 
known to have variable penetrance and phenotype.[39] 
The higher incidence of such defect in naïve patients observed in our study may be 
explained by the potential role of ERT to improve not the only clinical signs but also 
immune dysregulation, as demonstrated in our patient with a previous diagnosis of 
ALPS, who showed complete recovery of immunological impairment after 
appropriate treatment.  
 




As already reported in other PIRDs,[40] patients with GD of our cohort showed 
higher counts of DNTs, thus confirming that this finding cannot be considered a 
pathognomonic sign of ALPS. Interestingly, the patients of our cohort mostly 
showed an increase of IL-18 and DNTs but, unlike patients with ALPS, normal 
levels of IL-10, serum FAS, and vitamin B12, highlighting the important role of such 
biomarkers in the differential diagnosis of ALPS from other PIRDs or GD and 
indicating that the already revised diagnostic criteria of ALPS[15] need to be 
updated. In fact, in the last few years, knowledge of novel genetic defects causing 
PIRDs has dramatically increased, expanding the category of ALPS-like disorders, 
but no metabolic diseases have been reported to be associated with this phenotype so 
far. Our study shows, for the first time, that immune dysregulation can be the sign of 
a metabolic disorder such as GD and should be taken into consideration by clinicians 
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when patients presenting with this clinical pattern are referred. For this reason, the 
GBA1 gene should also be included in next-generation sequencing panels used to 
screen PIRDs because the identification of a specific underlying genetic defect can 
redirect care for targeted therapies, as already shown in other disorders such as Evans 
syndrome.[41][42] 
Finally, an incidental finding of our study, not reported before in GD and therefore 
worthy of mention, was the demonstration of a decrease or absence of CD8+NKT-
like cells in 90% of our patients. These cells are CD1d-independent T cells with NK 
markers, and therefore are distinct from CD1d-dependent invariant NKT cells.[43] 
CD8+NKT-like cells are especially noted as key players in the progression of 
chronic obstructive pulmonary disease and bronchiolitis obliterans and in conferring 
resistance to glucocorticoids.[44] We do not have the data to connect the decrease of 
CD8+NKT-like cells to sphingolipid dysfunction due to GBA deficiency and/or to 
lymphocyte apoptosis defect; therefore, this finding needs to be further investigated 
with specific studies.  
 
In conclusion, the presence of a FAS-mediated apoptosis defect leading to an ALPS-
like immune dysregulation in patients with GD suggests that this disorder should be 
excluded in the diagnostic work-up of ALPS and other PIRDs to administer the right 
treatment. Further studies are needed to confirm the role of impairment of the cell-
membrane lipid structure in the pathogenesis of such a defect and to evaluate 
prospectively, on a larger cohort of patients, the role of ERT in the normalization of 
Immune dysregulation. 
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